Biovica's DiviTum(R) TKa featured in TK IMPACT study at SABCS

22.11.2022 - UPPSALA, SE / ACCESSWIRE / November 22, 2022 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer monitoring, today announces that the unique study design of the TK IMPACT trial, using the DiviTum® TKa blood ...

Related Keywords

Sweden ,San Antonio ,Texas ,United States ,Anders Rylander ,Divitum Tka ,Nusaybaa Bagegni ,Oncology Division ,Washington University ,Biovica International ,Biovica International Registeredb Stock ,Principal Investigator ,San Antonio Breast Cancer Symposium ,Session Title ,Ongoing Clinical Trials ,Predictive Biomarkers ,Hormone Receptor Positive ,Metastatic Breast Cancer ,Patients Receiving ,Thymidine Kinase ,Nasdaq First North Premier Growth Market ,Biovica International Registered ,Biovica International Registeredb ,